1. [Susceptibility to fluconazole and itraconazole in isolates of Candida spp. from HIV-positive and HIV-negative patients].
- Author
-
Bernal S, Gutiérrez MJ, Serrano MC, Chávez M, Valverde A, Quindós G, and Mazuelos EM
- Subjects
- Candida isolation & purification, Humans, Microbial Sensitivity Tests, Antifungal Agents pharmacology, Candida drug effects, Fluconazole pharmacology, HIV Seronegativity, HIV Seropositivity microbiology, Itraconazole pharmacology
- Abstract
We studied the possible differences in the pattern of susceptibility to fluconazole and itraconazole in 393 isolates of Candida spp. from the oral cavity of HIV-positive patients and 102 isolates from HIV-negative patients with candidemia or candiduria. We used the broth microdilution method according to the NCCLS guidelines. We observed a decrease in the susceptibility to fluconazole in the group of HIV-positive patients in comparison to those who were HIV negative, especially in Candida albicans (MIC(90) 32 mg/l vs. 1 mg/l and Candida glabrata (MIC(90) 64 mg/l vs. 16 mg/l). Furthermore, we did not find any resistant strains in the HIV-negative group. For itraconazole, the MIC(90) was two dilutions greater in the HIV-positive patients, except for C. albicans, which had a much higher MIC(90) (4 mg/l vs. 0.12 mg/.). Therefore, the decrease in the susceptibility of Candida spp. in the HIV-positive patients must be taken into account when establishing a specific antifungal therapy.
- Published
- 2000